



## PreGen™ Technologies: Advancing the Fight Against Colorectal Cancer



Colorectal cancer is the most deadly and costly cancer among non-smoking men and women in the United States. This year, an estimated 57,000 Americans will die from the disease. In addition, 148,000 new cases will be diagnosed, with treatment costs totaling \$8.8 billion; nearly half of these are expected to die within five years, largely due to late-stage detection.



# Keep It Simple. Catch It Early.™

**EXACT**  
sciences





Applying Genomics to Eradicate Cancer™

## Keep It Simple. Catch It Early.

Early detection of colorectal cancer is the key to saving lives. Although physicians, advocacy groups, and the media have raised awareness of the disease and the importance of screening, compliance remains low, primarily due to the complex nature of existing screening methods:

- A small fraction of the 80 million Americans over 50 who should be screened annually *are actually screened*.
- Only 57% of those with colorectal cancer are diagnosed in the early, most treatable stages.
- 4 million Americans turn 50 each year, straining access to current screening resources.

Together, these facts underscore the need for a new screening approach that is safe, simple, and non-invasive.

Classification	Dukes' A	Dukes' B	Dukes' C	Dukes' D
<b>Development of Disease</b>				
<b>Cancer Progression</b>	Cancer confined to most superficial cell layers of colon or rectum (e.g., the top of the polyp).	Cancer may extend completely through wall of colon or rectum, but there is no lymph node involvement.	Cancer may extend completely through wall of colon or rectum and has spread to lymph nodes.	Metastatic disease. The cancer has spread to distant organs, such as the liver.
<b>Usual Treatment*</b>	Surgery	Surgery	Surgery and chemotherapy	Surgery and chemotherapy
<b>Estimated 5-Year Survival Rate</b>	95%	80%	50%	5%
<b>Percent Diagnosed at Stage</b>	37%		63%	

**Up to 95%  
of Lives Can  
Be Saved  
With Early  
Detection**


Two-thirds of patients present with advanced-stage disease (Dukes' C and D). According to the American Cancer Society, only 37% of colorectal cancers are currently detected at an early stage.

**\*Patient care is individualized based on overall medical circumstances.**


### The PreGen Screening Process



Physician sends requisition to lab



Lab provides collection materials to patient



Patient collects stool at home

Keep It



## Genomics Changes the Rules

Molecular changes are associated with carcinogenesis. These molecular changes are represented in the DNA shed from the cells of the entire colon each day and carried out of the body in stool.

**PreGen Technologies** are applied to isolate human DNA from bacterial DNA in stool and identify mutations in the human DNA associated with colorectal cancer. Multiple studies have demonstrated PreGen Technologies' high sensitivity and high specificity for colorectal cancer detection among various patient risk groups.

**PreGen-26™**, for use with high-risk patients who have known or suspected Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome. PreGen-26 is available today through Laboratory Corporation of America.

**PreGen-Plus™**, for use in patients at average risk for developing colorectal cancer. PreGen-Plus continues to be validated in ongoing clinical studies, two of which include thousands of patients. PreGen-Plus will be widely available in early 2003.



## The EXACT Sciences Difference: Safe, Simple, Non-invasive

Although PreGen Technologies are very sophisticated, the specimen collection process is very simple. Patients collect a single whole stool in the privacy and convenience of their own home. Sample collection requires:

- No bowel preparation
- No medication or dietary restrictions
- No sample manipulation


By simplifying the routine screening process, EXACT Sciences' patented technologies for specimen collection, preparation, and analysis directly address compliance issues. As a result, more patients may be safely screened without the discomfort of invasive procedures. Greater compliance, in turn, may lead to earlier detection of colorectal cancer and a reduction in mortality rates.

**PreGen-Plus  
will be widely  
available in  
early 2003.**

Simple. Catch It Early.  
Safe, Simple, Non-invasive




Patient returns specimen to lab



PreGen Technologies' stool DNA analysis is performed



Physician communicates results to patient  
Mutation identified: Leads to interventional colonoscopy  
No mutation identified: Continue routine screening program



## About EXACT Sciences

EXACT Sciences Corporation (NASDAQ: EXAS) is an applied genomics company located in Maynard, Massachusetts. Founded in 1995, the company's mission is to play a leading role in the eradication of mortality from common cancers by applying advances in the field of genomics to facilitate early detection of disease.

**EXACT**  
sciences

Applying Genomics to Eradicate Cancer™

EXACT Sciences Corporation

63 Great Road

Maynard, MA 01754

Tel: (978) 897-2800

Fax: (978) 897-3481

[www.exactsciences.com](http://www.exactsciences.com)

This test was developed and its performance characteristics determined by EXACT Sciences. It has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not currently required. The laboratory performing this test is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity testing.

PreGen, PreGen-26, and PreGen-Plus are trademarks and "Keep It Simple. Catch It Early" and "Applying Genomics To Eradicate Cancer" are service marks of EXACT Sciences Corporation. ©2002 EXACT Sciences Corporation. All rights reserved. Printed in US. 5/2002